My research interests thus relate primarily to end stage renal disease. In the dialysis unit we are currently involved in a multi-center NIH-sponsored trial called the AHEMO Trial@, which is looking at causes of long-term morbidity and mortality in the dialysis population and the effect on the dialysis prescription. In addition, our group has been active in maintenance of long-term hemodialysis access in the prospective of monitoring of vascular access to extend long-term graft survival. In the transplantation arena, we will soon be stating another multi-center trial to evaluate a new anti-lymphocyte antibody for the treatment of acute cellular rejection. This will be a multi-center randomized trial evaluating this new antibody versus OKT-3, which is currently standard of care. We are also interested in bone disease after transplantation and the prevention of acute rejection with other pharmacologic mechanisms and are establishing trials and interventions to evaluate these.
